Biology of Young Breast Cancer and Management in Pregnant Women
|
|
- Marianna Tyler
- 5 years ago
- Views:
Transcription
1 19 th BSMO Annual Meeting 2017 Breast Cancer Task Force Biology of Young Breast Cancer and Management in Pregnant Women Matteo Lambertini, MD ESMO Fellow Institut Jules Bordet, Brussels Diegem, Belgium February 24, 2017
2 Disclosure Information Relationship Relevant to this Session Lambertini, Matteo: No relevant relationship to disclose.
3 Introduction Plan of the Talk Biology of breast cancer in young women Young age, pathological breast cancer subtypes and prognosis Young age, molecular breast cancer subtypes and genomic alterations Breast cancer and pregnancy Breast cancer during pregnancy Pregnancy after breast cancer Concluding remarks
4 Introduction Plan of the Talk Biology of breast cancer in young women Young age, pathological breast cancer subtypes and prognosis Young age, molecular breast cancer subtypes and genomic alterations Breast cancer and pregnancy Breast cancer during pregnancy Pregnancy after breast cancer Concluding remarks
5 Breast Cancer in Young Women: Epidemiology Considerations Female Brain cancer (all ages) 10,000/y Female Stomach cancer (all ages) 10,000/y Female Liver cancer (all ages) 11,500/y Female Soft tissue sarcoma (all ages) 5,500/y DeSantis CE et al, CA Cancer J Clin 2016;66: Siegel RL et al, CA Cancer J Clin 2017;67:7-30
6 Breast Cancer in Young Women: Epidemiology Considerations Ghiasvand R et al, BMC Cancer 2014;14:343
7 Breast Cancer in Young Women: Young Women Advocates Statement Fertility preservation and pregnancyrelated issues is one of the five priority areas of concern for young women with breast cancer
8 Breast Cancer in Young Women: Clinical Practice Guidelines Partridge AH et al, The Breast 2014;23: Paluch-Shimon S et al, The Breast 2016;26:87-99
9 Introduction Plan of the Talk Biology of breast cancer in young women Young age, pathological breast cancer subtypes and prognosis Young age, molecular breast cancer subtypes and genomic alterations Breast cancer and pregnancy Breast cancer during pregnancy Pregnancy after breast cancer Concluding remarks
10 Pathological Features and Prognosis N=243,012 (Year ) < 40 (n=15,548) 40 (n=227,464) P-value T > 2cm 49.5% 35.5% < Node-positive 39.2% 25.2% < ER-negative 28.0% 14.2% < PgR-negative 30.1% 20.4% < Grade % 25.9% < Gnerlich JL et al, J Am Coll Surg 2009; 208:341-7
11 Pathological BC Subtype and Prognosis Higher incidence of TNBC and HER2-positive subtypes in young patients Azim HA et al, Breast Cancer Res 2014; 16:427
12 Pathological Features and Prognosis Young age as an independent factor associated with higher risk of disease relapse and death despite more aggressive treatments Increased risk of survival events Azim HA et al, Breast Cancer Res 2014; 16:427
13 Pathological BC Subtype and Prognosis Young patients have greater breast cancer mortality The effect of age on survival varies by breast cancer subtype: young age is particularly prognostic in women with luminal disease Breast cancer subtype Results in young patients Luminal A HR, 1.7; 95% CI, Luminal B HR, 1.2; 95% CI, HER2-positive HR, 1.1; 95% CI, Triple negative HR, 1.3; 95% CI, Partridge AH et al, J Clin Oncol 2016; 34:
14 Luminal BC Subtype and Prognosis Some young patients with luminal disease do have good outcomes SOFT Study No Chemotherapy TEXT Study No Chemotherapy Francis PA et al, N Engl J Med 2015;372: Pagani O et al, N Engl J Med 2014;371:107-18
15 Luminal BC Subtype and Prognosis 1 Increased risk of non-adherence 2 Importance of OFS in higher-risk patients Huiart L et al, Eur J Cancer 2012;48: Burstein HJ et al, J Clin Oncol 2016;34:
16 Luminal BC Subtype and Prognosis 3 Young patients with luminal disease remain at increased risk of late relapse Slide 15 Pan H et al, ASCO 2016
17 Luminal BC Subtype and Prognosis 3 Premenopausal patients may derive greater benefit from extended adjuvant endocrine therapy Goss PE et al, Ann Oncol 2013;24:355-61
18 Introduction Plan of the Talk Biology of breast cancer in young women Young age, pathological breast cancer subtypes and prognosis Young age, molecular breast cancer subtypes and genomic alterations Breast cancer and pregnancy Breast cancer during pregnancy Pregnancy after breast cancer Concluding remarks
19 Molecular BC Subtype and Prognosis Higher incidence of basal-like and HER2-enriched tumors in young patients Azim HA et al, Breast Cancer Res 2014; 16:427
20 Molecular BC Subtype and Prognosis The effect of age on survival varies by breast cancer subtype: young age remains particularly prognostic in women with luminal disease Azim HA et al, Clin Cancer Res 2012; 18:
21 Molecular Profiling of BC Gene-Expression Differences in Young Patients Enrichment of biological processes related to immature mammary cell population Higher expression of signatures related to endocrine resistance RANKL expression Mammary Stem cells Young patients Young patients Azim HA et al, Clin Cancer Res 2012; 18: Azim HA et al, BMC Med 2015; 13:266
22 Genomic Alterations Somatic Mutations Azim HA et al, BMC Med 2015; 13:266
23 Genomic Alterations Somatic Mutations GATA3 mutations.. Affect ER binding to DNA Modulate response of BC cells to estrogen signaling Promote tumor growth Associated with endocrine resistance Potential biologic reason of poorer prognosis of ER+ BC in young patients?? Courtesy of Azim HA Gaynor K et al, Horm Cancer 2013;4: Adomas AB et al, BMC Cancer 2014;14:278
24 Genomic Alterations Germline Mutations Tung N et al, J Clin Oncol 2016;34:1460-8
25 Genomic Alterations Germline Mutations 16 Eccles D et al, SABCS 2016;S2-3
26 Can Current Knowledge of Biology Translate in New Therapeutic Options for Young Patients? Target Rationale Agent RANKL GATA3 Stem cells / luminal progenitors BRCA COX-2 Courtesy of Azim HA High expression Modulation by pregnancy High prevalence in young Poor outcome of ER+ in young Involved in endocrine resistance High content in tumors arising at young age High mutation rates in young patients Implicated in post-pregnancy progression of cancer Denosumab (NCT ) Denosumab (ACTRN )?? Notch inhibitors?? Platinum salts (in clinical practice) PARPi (NCT ) Cox-2 inhibitors (NCT )
27 Introduction Plan of the Talk Biology of breast cancer in young women Young age, pathological breast cancer subtypes and prognosis Young age, molecular breast cancer subtypes and genomic alterations Breast cancer and pregnancy Breast cancer during pregnancy Pregnancy after breast cancer Concluding remarks
28 Breast Cancer During Pregnancy: Clinical Practice Guidelines Loibl S et al, Cancer 2006;106: Amant F et al, Eur J Cancer 2010;46: Loibl S et al, JAMA Oncol 2015;1:
29 Breast Cancer During Pregnancy: Epidemiological Considerations Breast cancer is one of the most frequently diagnosed malignancy during pregnancy Rare conditions: overall incidence of per 100,000 pregnancies Trend in mother s age at birth Trend in BC in young women Trend in BC during pregnancy Increased awareness needed! Mathews TJ et al, NCHS 2016;(232):1-8. Merlo FD et al, BCRT 2012;134: Loibl S et al, JAMA Oncol 2015;1:
30 Breast Cancer During Pregnancy: Biology and Prognosis BCP or BC < 5 years post-partum More aggressive pathological features and biology? More advanced stage at diagnosis? Sub-optimal treatments during pregnancy? BC < 5 years postpartum only BCP only Better OS with pregnancy Worse OS with pregnancy Hartman EK et al, Breast Cancer Res Treat 2016;160:347-60
31 Breast Cancer During Pregnancy: Biology and Prognosis No differences in the distribution of breast cancer subtypes Pregnant BC Patients Non-pregnant BC Patients Azim HA et al, Endocr Relat Cancer 2014;21:545-54
32 Breast Cancer During Pregnancy: Biology and Prognosis More advanced stage at diagnosis in women with BCP than nonpregnant patients but similar survival outcomes Amant F et al, J Clin Oncol 2013;31:2532-9
33 Breast Cancer During Pregnancy: Biology and Prognosis No differences in the survival outcomes between patients with BCP treated with FAC chemotherapy during pregnancy and matched control patients Disease-free survival Overall survival Litton JK et al, The Oncologist 2013;18:369-76
34 Breast Cancer During Pregnancy: Clinical Management Trimester of pregnancy at the time of diagnosis is the main issue! Loibl S et al, JAMA Oncol 2015;1:
35 Breast Cancer During Pregnancy: Clinical Management First-Trimester Second/Third-Trimesters Amant F et al, Lancet 2012;379:570-9
36 Breast Cancer During Pregnancy: Systemic Therapy - Chemotherapy Anthracyclines can be safely administered after the 1 st trimester of pregnancy No. of patients receiving anthracyline Type of anthracyline regimen used Gestational age at starting CT (months) Gestational age at delivery (months) Cardonick et al. (2010) Loibl et al. (2012) Murthy et al. (2014) AC, FAC, EC, FEC, anthracycline followed by taxanes A alone or E alone, AC or EC, FAC or FEC, anthracycline CMF, anthracycline taxanes FAC Spontaneous abortion 5% 1% - Malformations 4% 4% 4% Lambertini M et al, Expert Opin Drug Safety 2015;14:
37 Breast Cancer During Pregnancy: Systemic Therapy - Chemotherapy Taxanes can be safely administered after the 1 st trimester of pregnancy Taxanes during pregnancy Number - Breast cancer - Other - Paclitaxel - Docetaxel - Both Neonatal outcome - Mean gestational age at delivery - Foetal weight - Early preterm delivery - Foetal complications - Foetal malformations Week g 1 (2%) Anaemia (n=1), neutropenia (n=1) Pyloric stenosis (n=1) Zagouri F et al, Clin Breast Cancer 2013;13: Loibl S et al, Lancet Oncol 2012;13:887-96
38 Breast Cancer During Pregnancy: Systemic Therapy - Chemotherapy Loibl S et al, JAMA Oncol 2015;1:
39 Breast Cancer During Pregnancy: Systemic Therapy - Chemotherapy General rules to administer chemotherapy Use standard protocol Dose according to actual body weight Maintain dose-intensity Do not increase/decrease the dose Discontinue chemotherapy at week of gestation Loibl S et al, JAMA Oncol 2015;1:
40 Breast Cancer During Pregnancy: Systemic Therapy Timing of Chemotherapy 100% In patients diagnosed in the early third trimester of pregnancy (weeks 28-33), preterm delivery in order to start anticancer treatments in the post-partum period is the preferred option 80% 60% 40% 20% 0% 57% 15% 28% Disagree Neutral Agree Lambertini M et al, in preparation
41 Breast Cancer During Pregnancy: Systemic Therapy Outcomes of Children 96 exposed to chemotherapy Amant F et al, N Engl J Med 2015;373:
42 Breast Cancer During Pregnancy: Systemic Therapy Outcomes of Children Prematurity is more important than chemotherapy exposure for the cognitive development of children Cognitive outcome and gestational age Cognitive outcome and chemotherapy Amant F et al, N Engl J Med 2015;373:
43 Breast Cancer During Pregnancy: Systemic Therapy Outcomes of Children No difference in cognitive outcomes according to type of chemotherapy Amant F et al, N Engl J Med 2015;373:
44 Breast Cancer During Pregnancy: Systemic Therapy Outcomes of Children No difference in cardiac structure and functioning Amant F et al, N Engl J Med 2015;373:
45 Breast Cancer During Pregnancy: Systemic Therapy Fetal and Obstetric Care Increased risk of fetal/obstetric/birth complications No. of patients (No. with breast cancer) van Calsteren et al. (2010) 62 (34) Cardonick et al. (2010) 104 (104) Loibl et al. (2012) 179 (179) Fetal weight below 10 th percentile (CT vs no CT) 22% vs. 11% 7.5% vs. 0% 9% vs. 4% Obstetric complications (CT vs no CT) 27% vs. 9% 22% vs. NR 17% vs. 9% Fetal complications at birth (CT vs no CT) 11% vs. 5% 11% vs. 16% 15% vs. 4% Lambertini M et al, Expert Opin Drug Safety 2015;14:
46 Breast Cancer During Pregnancy: Systemic Therapy Fetal and Obstetric Care General Recommendations: Chemotherapy is generally safe beyond the first trimester of gestation. However, increased rates of premature delivery and growth retardation have been reported. Pregnancies where the fetus has been exposed to chemotherapy starting in the second trimester should be regarded as high-risk and regular fetal monitoring during gestation should be considered. Full-term delivery (i.e. 37 weeks) should be targeted whenever possible. Early or very early delivery should be discouraged, unless maternal and/or fetal health are endangered by the postponement of delivery until term. Peccatori FA et al, Ann Oncol 2013;24:v160-70
47 Breast Cancer During Pregnancy: Systemic Therapy Targeted agents Opposite considerations for targeted agents and chemotherapy Lambertini M et al, Cancer Treat Rev 2015;41:301-9
48 Breast Cancer During Pregnancy: Systemic Therapy Targeted agents Anti-HER2 and endocrine treatments are contraindicated during pregnancy Loibl S et al, JAMA Oncol 2015;1:
49 Breast Cancer During Pregnancy: Systemic Therapy Supportive Treatments Loibl S et al, JAMA Oncol 2015;1:
50 Introduction Plan of the Talk Biology of breast cancer in young women Young age, pathological breast cancer subtypes and prognosis Young age, molecular breast cancer subtypes and genomic alterations Breast cancer and pregnancy Breast cancer during pregnancy Pregnancy after breast cancer Concluding remarks
51 Pregnancy after Breast Cancer Who Cares? Only 3-7% manage to become subsequently pregnant Letourneau JM et al, Cancer 2012;118: Litton JK et al, Curr Treat Options Oncol 2012;13:137-45
52 Pregnancy after Cancer Breast cancer patients have the lowest chances among cancer survivors to become subsequently pregnant! Analysis adjusted for: -education level -previous pregnancy -age 70% lower chance of pregnancy compared to general population Peccatori F et al, Ann Oncol 2013;24:vi160-70
53 Inform the Patients about the Risk of Infertility: Early Referral ESMO GUIDELINES 2013 ASCO GUIDELINES 2013 Loren AW et al, J Clin Oncol 2013;31: Peccatori F et al, Ann Oncol 2013;24:vi
54 Pregnancy after Breast Cancer Is It Safe? 100% A pregnancy in breast cancer survivors may increase the risk of recurrence 80% 60% 40% 20% 0% 71% 17% 12% Disagree Neutral Agree Lambertini M et al, in preparation
55 Pregnancy after Breast Cancer Is It Safe? Better OS with pregnancy Worse OS with pregnancy Azim HA Jr et al, Eur J Cancer 2011;47:74-83
56 Pregnancy after Breast Cancer Is It Safe in ER+ Patients? Azim HA Jr et al, J Clin Oncol 2013;31:73-9
57 Pregnancy after Breast Cancer Is It Safe? Lambertini M et al, BMC Med 2016;14:1
58 Pregnancy Outcome and Safety of Interrupting Therapy for women with endocrine resposive breast cancer (POSITIVE) Target accrual: 514 patients Pagani O et al, Breast 2015;24:201-7
59 Introduction Plan of the Talk Biology of breast cancer in young women Young age, pathological breast cancer subtypes and prognosis Young age, molecular breast cancer subtypes and genomic alterations Breast cancer and pregnancy Breast cancer during pregnancy Pregnancy after breast cancer Concluding remarks
60 Take Home Messages (1/2) Age per se should not be considered a reason to administer more aggressive therapies Breast cancer arising in young women is biologically distinct beyond differences in breast cancer subtypes Specific attention should be paid in the management of young patients with luminal disease The investigation of tailored therapeutic strategies is warranted given their unique biology
61 Take Home Messages (2/2) Breast cancer during pregnancy should be managed in center with the adequate expertise The goal of treatments is to achieve full-term delivery Following available guidelines, the treatment of breast cancer during pregnancy is safe for both the mother and the baby Pregnancy after breast cancer can be considered safe also in patients with ER+ disease
Pregnancy and Breast Cancer. Elena Provenzano Addenbrookes Hospital Cambridge
Pregnancy and Breast Cancer Elena Provenzano Addenbrookes Hospital Cambridge Pregnancy and Breast Cancer Pregnancy and Breast Cancer 1. Pregnancy associated breast cancer: Histology, management, clinical
More informatione-session 381 BCY3 - Highlights of the 3rd ESO-ESMO Breast Cancer in Young Women International Conference
Expert: Dr Olivia Pagani, Oncology Institute of Southern Switzerland, Lugano, Switzerland Discussant: Dr Fedro Alessandro Peccatori, European Institute of Oncology, Milan, Italy e-session 381 BCY3 - Highlights
More informationDear doctor, what about a baby? Myths and facts
Dear doctor, what about a baby? Myths and facts OLIVIA PAGANI BREAST UNIT AND INSTITUTE OF ONCOLOGY OF SOUTHERN SWITZERLAND IBCSG Background About 15% of patients with BC are diagnosed during their reproductive
More informationA case of a BRCA2-mutated ER+/HER2 breast cancer during pregnancy
ESMO Preceptorship Programme Breast Cancer Lisbon 16,17 September 2016 Emanuela Risi Sandro Pitigliani Medical Oncology Department Hospital of Prato, Istituto Toscano Tumori, Prato, Italy A case of a BRCA2-mutated
More informationESMO Breast Cancer Preceptorship Singapore November Special Issues in Treatment of Young Women with Breast Cancer
ESMO Breast Cancer Preceptorship Singapore November 2017 Special Issues in Treatment of Young Women with Breast Cancer Prudence Francis MD Peter MacCallum Cancer Centre Melbourne, Australia Conflict of
More informationSYSTEMIC TREATMENT OF TRIPLE NEGATIVE BREAST CANCER
SYSTEMIC TREATMENT OF TRIPLE NEGATIVE BREAST CANCER Sunil Shrestha 1*, Ji Yuan Yang, Li Shuang and Deepika Dhakal Clinical School of Medicine, Yangtze University, Jingzhou, Hubei Province, PR. China Department
More informationBreast cancer & Fertility. Do we provide good information?
Breast cancer & Fertility. Do we provide good information? M Fastrez, C Houba 27 4 13 CHU S t Pierre Réseau IRIS University of Brussels We have no conflict of interest to disclose. Summary Introduction:
More informationEarly Stage Disease. Hope S. Rugo, MD Professor of Medicine Director Breast Oncology and Clinical Trials Education UCSF Comprehensive Cancer Center
SABCS 2014: Early Stage Disease Hope S. Rugo, MD Professor of Medicine Director Breast Oncology and Clinical Trials Education UCSF Comprehensive Cancer Center Topics for Discussion Chemotherapy plus 10
More informationLa preservazione della fertilità in oncologia: il carcinoma mammario come paradigma. Olivia Pagani Centro di Senologia dellasvizzera Italiana
La preservazione della fertilità in oncologia: il carcinoma mammario come paradigma Olivia Pagani Centro di Senologia dellasvizzera Italiana Centro di Senologia della Svizzera Italiana Pregnancy rate after
More informationEARLY BREAST CANCER, HER2-POSITIVE
EARLY BREAST CANCER, HER2-POSITIVE CLINICAL CASE DISCUSSION Elżbieta Senkus Medical University of Gdańsk Gdańsk, Poland esmo.org DISCLOSURES Honoraria: Amgen, Astellas, AstraZeneca, Bayer, BMS, Celgene,
More informationTriple negative breast cancer Biology and targeted therapy
Triple negative breast cancer Biology and targeted therapy MR SCI MED DR I BOŽOVIĆ -SPASOJEVIĆ INSTITUT ZA ONKOLOGIJU I RADIOLOGIJU SRBIJE I VA N A B O Z O V I C @ O U T L O O K. C O M Current challanges
More informationLa malattia triplo negativa metastatica: quali trattamenti nella pratica clinica?
2018 CARCINOMA MAMMARIO: I TRAGUARDI RAGGIUNTI E LE NUOVE SFIDE La malattia triplo negativa metastatica: quali trattamenti nella pratica clinica? Roma, 27 Ottobre 2018 Relatore: Francesca Poggio Disclosure
More informationTriple negative breast cancer -neoadjuvant and adjuvant systemic therapy
Triple negative breast cancer -neoadjuvant and adjuvant systemic therapy Sung-Bae Kim, MD, PhD Department of Oncology Asan Medical Center University of Ulsan College of Medicine Seoul, Korea DISCLOSURE
More informationTerapia sistemica neoadiuvante: in quali tumori? Quali risultati? Dott. Giacomo Pelizzari
Terapia sistemica neoadiuvante: in quali tumori? Quali risultati? Dott. Giacomo Pelizzari Neoadjuvant Treatment A window of opportunity Rational: Historically proposed to enable breast-conserving surgery
More informationTerapia hormonal y fertilidad
Madrid, 6 de Octubre de 2017 Terapia hormonal y fertilidad Sara López-Tarruella Cobo MD, PhD BC incidence focused on young patients Cumulative BC in females SEER 2000-05 7% Incidence BC in females by 6-year
More informationEARLY STAGE BREAST CANCER ADJUVANT CHEMOTHERAPY. Dr. Carlos Garbino
EARLY STAGE BREAST CANCER ADJUVANT CHEMOTHERAPY Dr. Carlos Garbino EARLY BREAST CANCER ADJUVANT CHEMOTHERAPY SUSTANTIVE DIFFICULTIES FOR A WORLDWIDE APPLICABILITY DUE TO IMPORTANT INEQUALITIES + IN DIFFERENT
More informationJohns Hopkins Clinical Update Webinar
Johns Hopkins Clinical Update Webinar Ben Ho Park, M.D., Ph.D. Department of Oncology Johns Hopkins University February 2015 This presentation is the intellectual property of the author/presenter. Contact
More informationAdjuvant Endocrine Therapy in Premenopausal Patients
Diagnosis and Treatment of Patients with Primary and Metastatic Breast Cancer Adjuvant Endocrine Therapy in Premenopausal Patients Adjuvant Endocrine Therapy in Premenopausal Patients Version 2002: Scharl
More information10/15/2012. Inflammatory Breast Cancer vs. LABC: Different Biology yet Subtypes Exist
Triple-Negative Breast Cancer: Optimizing Treatment for Locally Advanced Breast Cancer Beth Overmoyer MD Director, Inflammatory Breast Cancer Program Dana Farber Cancer Institute Overview Inflammatory
More informationOverview of peculiarities and therapeutic options for patients with breast cancer and a BRCA germline mutation
Overview of peculiarities and therapeutic options for patients with breast cancer and a BRCA germline mutation Dr Niklas Loman PhD MD Consultant oncologist Skåne University Hospital Lund, Suecia Prognosis
More informationLong Term Toxicity of Endocrine Therapy for premenopausal women with ER positive breast cancer
Global Breast Cancer Conference 2017 21 st Apr, 2017@Chezu Island Long Term Toxicity of Endocrine Therapy for premenopausal women with ER positive breast cancer Shinji Ohno, M.D., Ph.D., F.A.C.S. Breast
More informationNovel Preoperative Therapies for HER2-Positive Breast Cancer. Debu Tripathy, MD University of Southern California Norris Comprehensive Cancer Center
Novel Preoperative Therapies for HER2-Positive Breast Cancer Debu Tripathy, MD University of Southern California Norris Comprehensive Cancer Center Key Findings to Date in the Neoadjuvant Therapy of HER2+
More informationBREAST JOURNAL CLUB LONG-TERM OUTCOME RESULTS OF THE PHASE III PROMISE- GIM6 STUDY EVALUATING THE ROLE OF LHRH ANALOG
BREAST JOURNAL CLUB LONG-TERM OUTCOME RESULTS OF THE PHASE III PROMISE- GIM6 STUDY EVALUATING THE ROLE OF LHRH ANALOG (LHRHa) DURING CHEMOTHERAPY AS A STRATEGY TO REDUCE OVARIAN FAILURE IN EARLY BREAST
More informationMultidisciplinary approach to Young Breast Cancer Nursing. Department of Surgery, Soonchunhyang University, Cheonan Hospital Eunju Lee
Multidisciplinary approach to Young Breast Cancer Nursing Department of Surgery, Soonchunhyang University, Cheonan Hospital Eunju Lee I have nothing to disclose. No relevant financial relationships with
More informationAdjuvant Chemotherapy for Elderly Women with Breast Cancer: Matti S. Aapro, M.D. IMO Clinique de Genolier Switzerland
SIOG Berlin October 2009 Adjuvant Chemotherapy for Elderly Women with Breast Cancer: Immediate Benefit and Long-Term Risk Matti S. Aapro, M.D. IMO Clinique de Genolier Switzerland 1 2 BACKGROUND MESSAGE
More informationDr. Matteo Lambertini
CONGRESSO NAZIONALE AIOM GIOVANI SESSIONE: PREMIAZIONE MIGLIORI TRE LAVORI GIOVANI SOPPRESSIONE OVARICA CON LHRH ANALOGHI DURANTE CHEMIOTERAPIA PER LA PRESERVAZIONE DELLA FUNZIONE OVARICA E DELLA FERTILITÀ
More informationIdeal neo-adjuvant Chemotherapy in breast ca. Dr Khanyile Department of Medical Oncology, University of Pretoria
Ideal neo-adjuvant Chemotherapy in breast ca Dr Khanyile Department of Medical Oncology, University of Pretoria When is neo-adjuvant Chemo required? Locally advanced breast ca: - Breast conservative surgery
More informationTNBC: What s new Déjà vu All Over Again? Lucy R. Langer, MD MSHS Compass Oncology - SABCS 2016 Review February 21, 2017
TNBC: What s new Déjà vu All Over Again? Lucy R. Langer, MD MSHS Compass Oncology - SABCS 2016 Review February 21, 2017 The problem with TNBC 1. Generally more aggressive 2. ONLY chemotherapy 3. No other
More informationUse of Ovarian Suppression and Ablation in Breast Cancer Treatment
Use of Ovarian Suppression and Ablation in Breast Cancer Treatment Dr Marina Parton Consultant Medical Oncologist Royal Marsden and Kingston Hospitals Overview Breast cancer phenotypes Use of ovarian manipulation
More informationAdjuvant chemotherapy in older breast cancer patients: how to decide?
Adjuvant chemotherapy in older breast cancer patients: how to decide? H. Wildiers University Hospitals Leuven Belgium Wildiers H, Kunkler I, Lancet Oncol 2007 Biganzoli L, Wildiers H, Lancet Oncol. 2012
More informationINITIAL EVALUATION. Ductal carcinoma in situ 2 (DCIS) See Ductal Carcinoma In Situ Breast Cancer Non-Invasive Algorithm
Pregnancy and Breast Cancer Page of 5 INITIAL EVALUATION Palpable mass greater than 2 weeks History and physical Bilateral mammogram with fetal shielding/ultrasound of breast and nodal basins Core biopsy
More informationEvolving Insights into Adjuvant Chemotherapy. Joyce O Shaughnessy, MD Baylor Sammons Cancer Center Texas Oncology US Oncology
Evolving Insights into Adjuvant Chemotherapy Joyce O Shaughnessy, MD Baylor Sammons Cancer Center Texas Oncology US Oncology 80 70 60 50 40 30 20 10 0 EBCTCG 2005/6 Overview Control Arms with No Systemic
More informationBreast Cancer and Pregnancy
Breast Cancer and Pregnancy F. Cardoso, MD Director, Breast Unit, Champalimaud Clinical Center, Lisbon, Portugal ESO Breast Cancer Program Coordinator ESMO Board of Directors & NR Committee Chair EORTC
More informationCarrier Frequency. Breast Cancer and Treatment Options in Patients with BRCA1/2 mutations. Olivia Pagani On behalf of Bella Kaufman
Breast Cancer and Treatment Options in Patients with BRCA1/2 mutations Olivia Pagani On behalf of Bella Kaufman Carrier Frequency Prevalence of an altered disease gene in a given population 1 Background
More informationBreast Cancer and Treatment Options in Patients with BRCA1/2 mutations. Olivia Pagani On behalf of Bella Kaufman
Breast Cancer and Treatment Options in Patients with BRCA1/2 mutations Olivia Pagani On behalf of Bella Kaufman Carrier Frequency Prevalence of an altered disease gene in a given population Background
More informationBreast Cancer in Young Women News from the BCY3 Consensus Conference
Expert Discussion Breast Care 2016;11:432 435 DOI: 10.1159/000454873 Published online: December 13, 2016 Breast Cancer in Young Women News from the BCY3 Consensus Conference Chair: Shani Paluch-Shimon
More informationThe Role of Pathologic Complete Response (pcr) as a Surrogate Marker for Outcomes in Breast Cancer: Where Are We Now?
1 The Role of Pathologic Complete Response (pcr) as a Surrogate Marker for Outcomes in Breast Cancer: Where Are We Now? Terry Mamounas, M.D., M.P.H., F.A.C.S. Medical Director, Comprehensive Breast Program
More informationNon-anthracycline Adjuvant regimens in Early Breast Cancer. Yeesoo Chae, MD, PhD Medical Oncology Kyungpook National University Medical Center
Non-anthracycline Adjuvant regimens in Early Breast Cancer Yeesoo Chae, MD, PhD Medical Oncology Kyungpook National University Medical Center Contents Role of Anthracyclines in adjuvant treatment EBCTCG2012
More informationPoint of View on Early Triple Negative
Point of View on Early Triple Negative Valentina Rossi, MD UOSD Oncologia dei Tumori della Mammella Azienda Ospedaliera S.Camillo-Forlanini VRossi@scamilloforlanini.rm.it Outline Neoadjuvant Setting IPSY-2
More informationTriple Negative Breast Cancer. Eric P. Winer, MD Dana-Farber Cancer Institute Harvard Medical School Boston, MA October, 2008
Triple Negative Breast Cancer Eric P. Winer, MD Dana-Farber Cancer Institute Harvard Medical School Boston, MA October, 2008 Triple Negative Breast Cancer 15% 25% Triple Negative 20% HER2+ ER+ Low Grade
More informationSystemic Therapy Considerations in Inflammatory Breast Cancer
Systemic Therapy Considerations in Inflammatory Breast Cancer Shani Paluch-Shimon, MBBS, MSc Director, Breast Oncology Unit Shaare Zedek Medical Centre, Jerusalem Israel Disclosures Roche: Speakers bureau,
More informationConsiderations in Adjuvant Chemotherapy. Joyce O Shaughnessy, MD Baylor Sammons Cancer Center Texas Oncology US Oncology
Considerations in Adjuvant Chemotherapy Joyce O Shaughnessy, MD Baylor Sammons Cancer Center Texas Oncology US Oncology 80 70 60 50 40 30 20 10 0 EBCTCG 2005/6 Overview Control Arms with No Systemic Treatment
More informationPostoperative Adjuvant Chemotherapies. Stefan Aebi Luzerner Kantonsspital
Postoperative Adjuvant Chemotherapies Stefan Aebi Luzerner Kantonsspital stefan.aebi@onkologie.ch Does Chemotherapy Work in Older Patients? ER : Chemotherapy vs nil Age
More informationAneurin Bevan University Health Board Breast Cancer and Pregnancy Guideline
Breast Cancer and Pregnancy Guideline N.B. Staff should be discouraged from printing this document. This is to avoid the risk of out of date printed versions of the document. The Intranet should be referred
More informationSystemic Therapy for Locally Advanced Breast Cancer
Systemic Therapy for Locally Advanced Breast Cancer Soo-Chin Lee Head & Senior Consultant Department of Haematology-Oncology National University Cancer Institute, Singapore Clinical Care Senior Principal
More informationImpact of BMI on pathologic complete response (pcr) following neo adjuvant chemotherapy (NAC) for locally advanced breast cancer
Impact of BMI on pathologic complete response (pcr) following neo adjuvant chemotherapy (NAC) for locally advanced breast cancer Rachna Raman, MD, MS Fellow physician University of Iowa hospitals and clinics
More informationEndocrine treatment might NOT be the preferred option in Hrpos MBC. Dr. Mircea Dediu Sanador Hospital Bucharest Summer School Bucharest 2015
Endocrine treatment might NOT be the preferred option in Hrpos MBC Dr. Mircea Dediu Sanador Hospital Bucharest Summer School Bucharest 2015 Overall survival not improved by the AI treatment Benefit in
More informationAdvances in Breast Cancer Therapeutics in the Adjuvant and Metastatic Settings. Eve Rodler, MD University of California at Davis October 2016
Advances in Breast Cancer Therapeutics in the Adjuvant and Metastatic Settings Eve Rodler, MD University of California at Davis October 2016 17th Annual Advances in Oncology September 30-October 1, 2016
More informationASCO 2017 BREAST CANCER HIGHLIGHTS
Post-ASCO 24 th June 2017, Dolce La Hulpe, Belgium ASCO 2017 BREAST CANCER HIGHLIGHTS Martine J. Piccart-Gebhart, MD, PhD Jules Bordet Institute, Brussels, Belgium Université Libre de Bruxelles Breast
More informationTherapeutic Targets for Triple- Negative Breast Cancer: Focus on Platinums and EGFR Inhibition
Therapeutic Targets for Triple- Negative Breast Cancer: Focus on Platinums and EGFR Inhibition Lisa A Carey, MD Disclosures for Lisa A Carey, MD No real or apparent conflicts of interest to disclose Basal-Like
More information8/8/2011. PONDERing the Need to TAILOR Adjuvant Chemotherapy in ER+ Node Positive Breast Cancer. Overview
Overview PONDERing the Need to TAILOR Adjuvant in ER+ Node Positive Breast Cancer Jennifer K. Litton, M.D. Assistant Professor The University of Texas M. D. Anderson Cancer Center Using multigene assay
More informationDisclosure of Relevant Financial Relationships. Breast Pathology Evening Specialty Conference Case #4. Clinical Case: Pathologic Features
Breast Pathology Evening Specialty Conference Case #4 K.P. Siziopikou, MD, PhD Professor of Pathology Director of Breast Pathology and Breast Pathology Fellowship Program Northwestern University Feinberg
More informationAdjuvan Chemotherapy in Breast Cancer
Adjuvan Chemotherapy in Breast Cancer Prof Dr Adnan Aydıner Istanbul University, Oncology Institute aa1 Slide 1 aa1 adnan aydiner; 17.02.2008 15-Year Reductions in Recurrence and Disease-Specific Mortality
More informationShould premenopausal HR+ve breast cancer receive LHRH?
Should premenopausal HR+ve breast cancer receive LHRH? Hesham Elghazaly, MD Prof. Clinical Oncology, Ain Shams University President of the BGICS Should premenopausal HR+ve breast cancer receive LHRH? NO?
More informationORMONOTERAPIA ADIUVANTE: QUALE LA DURATA OTTIMALE? MARIANTONIETTA COLOZZA
ORMONOTERAPIA ADIUVANTE: QUALE LA DURATA OTTIMALE? MARIANTONIETTA COLOZZA THE NATURAL HISTORY OF HORMONE RECEPTOR- POSITIVE BREAST CANCER IS VERY LONG Recurrence hazard rate 0.3 0.2 0.1 0 ER+ (n=2,257)
More informationAny News in EBC? Ann H. Partridge, MD, MPH Dana-Farber Cancer Institute November 11, 2016
Any News in EBC? Ann H. Partridge, MD, MPH Dana-Farber Cancer Institute November 11, 2016 Yes! Age disparities vary by tumor subtype Genomic risk prediction data in young women Adjuvant systemic therapy
More informationClinical Research on PARP Inhibitors and Triple-Negative Breast Cancer (TNBC)
Clinical Research on PARP Inhibitors and Triple-Negative Breast Cancer (TNBC) Eric P Winer, MD Disclosures for Eric P Winer, MD No real or apparent conflicts of interest to disclose Key Topics: PARP and
More informationAdjuvant Endocrine Therapy in Premenopausal Patients
Diagnosis and Treatment of Patients with Primary and Metastatic Breast Cancer Adjuvant Endocrine Therapy in Premenopausal Patients Adjuvant Endocrine Therapy in Premenopausal Patients www.agoonline.de
More information03/14/2019. GnRH Analogs for Fertility Preservation: What are the Data? Educational Objectives. Outline
GnRH Analogs for Fertility Preservation: What are the Data? AHN-JH SKCCC Current Topics in Breast Cancer Symposium Karen Lisa Smith MD MPH Assistant Professor Johns Hopkins Breast and Cancer Program March
More informationSummary BREAST CANCER - Early Stage Breast Cancer... 3
ESMO 2016 Congress 7-11 October, 2016 Copenhagen, Denmark Table of Contents Summary... 2 BREAST CANCER - Early Stage Breast Cancer... 3 Large data analysis reveals similar survival outcomes with sequential
More informationBarbara Pistilli Comité de Pathologie Mammaire. Vendredi 21 septembre 2018 #2018OBSERVANCE
FÉDÉRER LA RECHERCHE ET L INNOVATION MÉDICALE EN CANCÉROLOGIE Etat des lieux des difficultés d observance aux différents types de traitement tout au long du parcours de soin et difficulté des équipes médicales
More informationWith the exception of skin cancer, breast cancer is
Maternal and Neonatal Outcomes of for Breast Cancer in Pregnancy Elyce Cardonick, MD, Dzhamala Gilmandyar, MD, and Robert A. Somer, MD Original Research OBJECTIVE: To estimate the effect of dose-dense
More informationPerspectivas de desarrollo de la inmunoterapia en cáncer de mama hereditario. Luis de la Cruz Merino Oncología Médica HUVMacarena (Sevilla)
Perspectivas de desarrollo de la inmunoterapia en cáncer de mama hereditario Luis de la Cruz Merino Oncología Médica HUVMacarena (Sevilla) Outline Immunology and breast cancer Clinical trials with modern
More informationThe Three Ages of Systemic Adjuvant Therapy for EBC
The Three Ages of Systemic Adjuvant Therapy for EBC 1896-2018 Nicholas Wilcken Westmead Hospital Petersham Institute University of Sydney Questions to be answered (concentrating on chemotherapy) Why should
More information38 years old, premenopausal, had L+snbx. Pathology: IDC Gr.II T-1.9cm N+2/4sn ER+100%st, PR+60%st, Her2-neg, KI %
38 years old, premenopausal, had L+snbx Pathology: IDC Gr.II T-1.9cm N+2/4sn ER+100%st, PR+60%st, Her2-neg, KI67 5-10% Question: What will you do now? 1. Give adjuvant chemotherapy 2. Send for Oncotype
More informationOnco-fertility. Fertility issues in young women with breast cancer in Japan. National Cancer Center Hospital, Tokyo Chikako Shimizu, MD
Onco-fertility Fertility issues in young women with breast cancer in Japan National Cancer Center Hospital, Tokyo Chikako Shimizu, MD COI disclosure Chikako Shimizu receives contracted research fund from
More informationIntensifiedCT with stemcellrescue for high-riskprimary breastcancer
IntensifiedCT with stemcellrescue for high-riskprimary breastcancer Paolo PEDRAZZOLI SC Oncologia p.pedrazzoli@smatteo.pv.it Trend of HDC BC in Europe: 1992-2012: data from the EBMT registry Phase III
More informationSYSTEMIC THERAPY OPTIONS FOR BREAST CANCER IN 2014
SYSTEMIC THERAPY OPTIONS FOR BREAST Oncology Day 2014 CANCER IN 2014 Dr. Katherine Enright, M.D., M.P.H., F.R.C.P.(C) Katherine.enright@Trilliumhealthpartners.ca OBJECTIVES 1. Outline an approach to the
More informationSession thématisée Les Innovations diagnostiques en cancérologie
10 èmes Journées Scientifiques du Cancéropôle Nord-Ouest 10-12 mai 2017, Deauville Session thématisée Les Innovations diagnostiques en cancérologie Les signatures multigéniques pronostiques dans le cancer
More informationThe effect of delayed adjuvant chemotherapy on relapse of triplenegative
Original Article The effect of delayed adjuvant chemotherapy on relapse of triplenegative breast cancer Shuang Li 1#, Ding Ma 2#, Hao-Hong Shi 3#, Ke-Da Yu 2, Qiang Zhang 1 1 Department of Breast Surgery,
More informationSesiones interhospitalarias de cáncer de mama. Revisión bibliográfica 4º trimestre 2015
Sesiones interhospitalarias de cáncer de mama Revisión bibliográfica 4º trimestre 2015 Selected papers Prospective Validation of a 21-Gene Expression Assay in Breast Cancer TAILORx. NEJM 2015 OS for fulvestrant
More informationPrognostic significance of stroma tumorinfiltrating lymphocytes according to molecular subtypes of breast cancer
Prognostic significance of stroma tumorinfiltrating lymphocytes according to molecular subtypes of breast cancer Hee Jung Kwon, Nuri Jang, Min Hui Park, Young Kyung Bae Department of Pathology, Yeungnam
More informationFertility and breast cancer
Review Fertility and breast cancer Joanna Kufel-Grabowska, MD, PhD Greater Poland Cancer Centre in Poznań, Poland Received: 14.07.2016. Accepted: 25.09.2016. ABSTRACT Breast cancer is the most common cancer
More informationNeoadjuvant chemotherapy (NACT) in young women with breast cancer. Hanne Melgaard Nielsen, MD Ph.D Department of Oncology, Aarhus University Hospital
Neoadjuvant chemotherapy (NACT) in young women with breast cancer Hanne Melgaard Nielsen, MD Ph.D Department of Oncology, Aarhus University Hospital Young women according to EUSOMA guidelines Is under
More informationAnthracyclines for Breast Cancer? Are Adjuvant Anthracyclines Dispensible? Needs to be Answered in a Large Prospective Trial
Anthracyclines for Breast Cancer? Are Adjuvant Anthracyclines Dispensible? Needs to be Answered in a Large Prospective Trial Joanne L. Blum, MD, PhD Baylor-Sammons Cancer Dallas, TX Early Breast Cancer
More informationFollow-up Care of Breast Cancer Patients
Follow-up Care of Breast Cancer Patients Dr. Simon D. Baxter, MD, FRCPC Medical Oncologist BC Cancer Kelowna Clinical Instructor, Dept of Medicine University of British Columbia 24 November 2018 Disclosures
More informationENFERMEDAD AVANZADA Qué hacemos con el triple negativo? Nuevas aproximaciones
ENFERMEDAD AVANZADA Qué hacemos con el triple negativo? Nuevas aproximaciones Javier Cortes, Hospital Universitario Ramon y Cajal, Madrid Vall d Hebron Institute of Oncology (VHIO), Barcelona Triple Negative
More informationAdjuvant Endocrine Therapy: How Long is Long Enough?
Adjuvant Endocrine Therapy: How Long is Long Enough? Harold J. Burstein, MD, PhD Dana-Farber Cancer Institute Harvard Medical School Boston, Massachusetts hburstein@partners.org I have no conflicts to
More informationLo Studio Geparsepto. Alessandra Fabi Oncologia Medica 1
Lo Studio Geparsepto Alessandra Fabi Oncologia Medica 1 nab-paclitaxel Versus Solvent-Based Paclitaxel in Neoadjuvant Chemotherapy for Early Breast Cancer (GeparSepto GBG 69): A Randomised, Phase III Trial
More informationOncotype DX testing in node-positive disease
Should gene array assays be routinely used in node positive disease? Yes Christy A. Russell, MD University of Southern California Oncotype DX testing in node-positive disease 1 Validity of the Oncotype
More informationRole of Primary Resection for Patients with Oligometastatic Disease
GBCC 2018, April 6, Songdo ConvensiA, Incheon, Korea Panel Discussion 4, How Can We Better Treat Patients with Metastatic Disease? Role of Primary Resection for Patients with Oligometastatic Disease Tadahiko
More informationClinico- Pathological Features And Out Come Of Triple Negative Breast Cancer
Clinico- Pathological Features And Out Come Of Triple Negative Breast Cancer Dr. HassanAli Al-Khirsani, MBChB, CABM, F.I.C.M.S AL-Sadder teaching hospital, oncology unit Dr. Nasser Ghaly Yousif, MBChB,G.P.
More informationImmunotherapy for Breast Cancer Clinical Development
Immunotherapy for Breast Cancer Clinical Development Laurence Buisseret, MD, PhD Breast Cancer Translational Research Laboratory Institut Jules Bordet Université Libre de Bruxelles (ULB) ESMO preceptorship
More informationTriple Negative Breast Cancer
Triple Negative Breast Cancer Prof. Dr. Pornchai O-charoenrat Division of Head-Neck & Breast Surgery Department of Surgery Faculty of Medicine Siriraj Hospital Breast Cancer Classification Traditional
More informationTriple Negative Breast Cancer: Part 2 A Medical Update
Triple Negative Breast Cancer: Part 2 A Medical Update April 29, 2015 Tiffany A. Traina, MD Breast Medicine Service Memorial Sloan Kettering Cancer Center Weill Cornell Medical College Overview What is
More informationNeo-adjuvant and adjuvant treatment for HER-2+ breast cancer
Neo-adjuvant and adjuvant treatment for HER-2+ breast cancer Angelo Di Leo «Sandro Pitigliani» Medical Oncology Unit Hospital of Prato Istituto Toscano Tumori Prato, Italy NOAH: Phase III, Open-Label Trial
More informationFollow-up Care of Breast Cancer Patients
Follow-up Care of Breast Cancer Patients Dr. Simon D. Baxter, MD, FRCPC Medical Oncologist BC Cancer Kelowna Clinical Instructor, Dept of Medicine University of British Columbia 19 April 2018 Disclosures
More informationSystemic Therapy of HER2-positive Breast Cancer
Systemic Therapy of HER2-positive Breast Cancer Tanja Cufer, MD, PhD University Clinic Golnik, Medical Faculty Ljubljana, Slovenia ESO ESMO Masterclass, Belgrade 2017 Relative Risk HER2-positive Breast
More informationDieta Brandsma, Department of Neuro-oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands
What is hot in breast cancer brain metastases? Dieta Brandsma, Department of Neuro-oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands 8th Annual Brain Metastases Research and Emerging Therapy
More informationPregnancy in the middle of adjuvant treatment of Her2 positive breast cancer
ESMO Preceptorship Programme ESMO Preceptorship ADOLESCENTS & YOUNG ADULTS MALIGNANCIES Lugano, Switzerland 11-12 May 2018 Petra Vuković, University Hospital for Tumors, University Hospital Center Sestre
More informationBreast Cancer in Young Women Arrow Project June 6 th Aharona Gutman Dr. Shani Paluch-Shimon
Breast Cancer in Young Women Arrow Project June 6 th 2013 Aharona Gutman Dr. Shani Paluch-Shimon Overview - Breast Cancer in Young Women 10% of breast cancers are diagnosed in women under 40 Breast cancer
More informationWhat is new in HR+ Breast Cancer? Olivia Pagani Breast Unit and Institute of oncology of Southern Switzerland
What is new in HR+ Breast Cancer? Olivia Pagani Breast Unit and Institute of oncology of Southern Switzerland Outline Early breast cancer Advanced breast cancer Open questions Outline Early breast cancer
More informationSubtype-directed therapy of TNBC Global Breast Cancer Conference 2015 & 4th International Breast Cancer Symposium Jeju Island, Korea, April 2015
Subtype-directed therapy of TNBC Global Breast Cancer Conference 2015 & 4th International Breast Cancer Symposium Jeju Island, Korea, April 2015 Ruth M. O Regan, MD Visiting Professor and Division Chief
More informationMultigene Testing in NCCN Breast Cancer Treatment Guidelines, v1.2011
Multigene Testing in NCCN Breast Cancer Treatment Guidelines, v1.2011 Robert W. Carlson, M.D. Professor of Medicine Stanford University Chair, NCCN Breast Cancer Treatment Guidelines Panel Selection of
More informationBreast cancer in young women: impact of pregnancy on biology and outcome
ESMO Translational Research Fellowship Breast cancer in young women: impact of pregnancy on biology and outcome Hatem A. Azim Jr., MD, MSc. (Oct 2010 Sep 2012) Final Report Host Institute: Mentor: Project
More informationGene Signatures in Breast Cancer: Moving Beyond ER, PR, and HER2? Lisa A. Carey, M.D. University of North Carolina USA
Gene Signatures in Breast Cancer: Moving Beyond ER, PR, and HER2? Lisa A. Carey, M.D. University of North Carolina USA When Are Biomarkers Ready To Use? Same Rules for Gene Expression Panels Key elements
More informationAdjuvant Chemotherapy TNBC & HER2 Subtype
Adjuvant Chemotherapy TNBC & HER2 Subtype 2015.08.15 Gun Min Kim Yonsei Cancer Center Division of Medical Oncology Department of Internal Medicine Yonsei University College of Medicine gmkim77@yuhs.ac
More informationSystemic Therapy of HER2-positive Breast Cancer
Systemic Therapy of HER2-positive Breast Cancer Tanja Cufer, MD, PhD University Clinic Golnik, Medical Faculty Ljubljana, Slovenia ESO ESMO Masterclass, Belgrade 2018 HER2-positive Breast Cancer Adjuvant
More informationCancer du sein métastatique et amélioration de la survie Pr. X. Pivot
Cancer du sein métastatique et amélioration de la survie Pr. X. Pivot Date of preparation: November 2015. EU0250i TTP/PFS Comparaisons First line metastatic breast cancer Monotherapy Docetaxel Chan 1999
More informationESMO SUMMIT MIDDLE EAST 2018
ESMO SUMMIT MIDDLE EAST 2018 Breast Clinical Cases Presentation Hampig Raphael Kourie, MD, MSc, MBioethics Faculty of Medicine, Saint Joseph University of Beirut, Lebanon 6-7 April 2018, Dubai, UAE CONFLICT
More information